SpringWorks Hopes Pediatric Plus Adult Data Make Mirdametinib Go-To For NF1-PN

The company plans to file for FDA approval in the first half of 2024 as it eyes a market of about 40,000 adult and pediatric patients in the US.

SpringWorks announced data from its Phase IIb trial of mirdametinib in the rare disease NF1. • Source: Shutterstock

SpringWorks Therapeutics Inc. has a potentially significant market opportunity with positive data in hand from its Phase IIb ReNeu trial of mirdametinib in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), compared with existing options that are only available for pediatric patients.

SpringWorks announced the results of the trial on 16 November, stating that it plans to seek US Food and Drug Administration for the drug, a MEK inhibitor, during the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

23 May 2025

• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy